Bain Capital Life Sciences Investors’s X4 Pharmaceuticals XFOR Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.2M	Hold	7,967,454	–	–	2.21%	11
2026 Q1	$32.9M	Hold	7,967,454	–	–	2.97%	7
2025 Q4	$31.9M	Buy	7,967,454 +5,530,866	+227%	+$20.1M	2.44%	8
2025 Q3	$8.33M	Buy	2,436,588 +1,872,729	+332%	+$4.83M	0.55%	15
2025 Q2	$1.07M	Hold	563,859	–	–	0.13%	22
2025 Q1	$4M	Hold	563,859	–	–	0.59%	15
2024 Q4	$12.4M	Hold	563,859	–	–	1.46%	13
2024 Q3	$11.3M	Hold	563,859	–	–	1.18%	13
2024 Q2	$9.81M	Hold	563,859	–	–	1.08%	15
2024 Q1	$23.5M	Hold	563,859	–	–	1.89%	13
2023 Q4	$14.2M	Buy	563,859 +31,839	+6%	+$774K	1.36%	17
2023 Q3	$17.4M	Hold	532,020	–	–	1.95%	13
2023 Q2	$31M	Buy	532,020 +125,270	+31%	+$6.44M	3.19%	11
2023 Q1	$10.6M	Hold	406,750	–	–	1.33%	22
2022 Q4	$12.1M	Buy	406,750 +193,769	+91%	+$9.18M	1.35%	20
2022 Q3	$10.9M	Buy	212,981 +112,330	+112%	+$3.88M	1.3%	20
2022 Q2	$2.91M	Hold	100,651	–	–	0.34%	34
2022 Q1	$5.28M	Buy	100,651 +4,433	+5%	+$254K	0.51%	28
2021 Q4	$6.61M	Buy	96,218 +25,567	+36%	+$3.23M	0.52%	26
2021 Q3	$11.2M	Hold	70,651	–	–	0.7%	23
2021 Q2	$13.8M	Hold	70,651	–	–	0.9%	21
2021 Q1	$18.2M	Buy	70,651 +15,701	+29%	+$4.13M	1.03%	19
2020 Q4	$10.6M	Hold	54,950	–	–	0.67%	20
2020 Q3	$11.2M	Hold	54,950	–	–	1.04%	18
2020 Q2	$15.4M	Hold	54,950	–	–	1.61%	13
2020 Q1	$16.5M	Hold	54,950	–	–	2.79%	8
2019 Q4	$17.6M	Buy	+54,950	New	+$19.7M	2.63%	7

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bain Capital Life Sciences Investors's XFOR Position: Q2 2026 in Review

Bain Capital Life Sciences Investors held its X4 Pharmaceuticals (XFOR) position steady in Q2 2026 at 7,967,454 shares worth $37.2M. The position accounts for 2.21% of the portfolio, ranked #11.

Bain Capital Life Sciences Investors first reported a position in XFOR in Q4 2019 and has held it in 27 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Bain Capital Life Sciences Investors held 7,967,454 shares of X4 Pharmaceuticals worth $37.2M as of Q2 2026.
Bain Capital Life Sciences Investors left its X4 Pharmaceuticals share count unchanged in Q2 2026.
X4 Pharmaceuticals made up 2.21% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #11 holding.
Bain Capital Life Sciences Investors first reported a position in X4 Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.